Select Medical: Going Private, but Critical Illness Drags
The Take-Private: A Defining Shift
The headline for the quarter is the continuing march toward privatization. As “On March 2, 2026, we announced that Select Medical Holdings Corporation entered into an agreement to be acquired by a consortium led by our Executive Chairman, Robert Ortenzio, together with Martin Jackson and Welsh, Carson, Anderson & Stowe.” — Thomas Mullen, Chief Executive Officer · 2026-05-01 The HSR waiting period expired on April 27, and the deal is expected to close mid-2026. This is a private transaction that reframes all other discussion: the company is moving away from public scrutiny to focus on long-term value creation. The additional $1 billion term loan at SOFR+3% will increase leverage, as the deal closes.
We are maintaining our full-year 2026 guidance. We continue to expect revenue to range between $5.6 billion and $5.8 billion and adjusted EBITDA between $520 million and $540 million.
The Diverging Story: IRF vs. Critical Illness
Operationally, Q1 2026 was a tale of two segments. The inpatient rehabilitation (IRF) division continues to shine, with revenue up over 14% and adjusted EBITDA up 15%, as occupancy reached 83%. The growth is being driven by development—166 beds added already, with 275 more planned. In contrast, the critical illness recovery hospital (CIRH) segment saw EBITDA decline 15% as Medicare Advantage conversion rates fell. Tom Mullen acknowledged the pressure: “We did see a decrease in conversion for Medicare Advantage in the first quarter, and it was more so in our long-term acute care hospitals, as well as our inpatient rehab also saw a decline.” — Thomas Mullen, Chief Executive Officer · 2026-05-01 This is a recurring theme—Medicare advantage denials have been a persistent headwind, but the magnitude in Q1 was notable, with CFO Michael Malatesta quantifying the year-over-year impact at approximately $13-14 million.
Regulatory Environment: A Mixed Bag
On the regulatory front, the proposed CMS rules for FY2027 provide some relief. The standard federal payment rate for IRF is proposed to increase ~2.6%, and the LTACH rate by 2.66%, with the high-cost outlier threshold held steady—a positive after years of escalation. As “the fixed loss threshold in the last 4 years has gone from $38,000 to $59,000 then to $77,000... we did get a bit of a break with it being at $79,000” — Robert Ortenzio, Executive Chairman and Co-Founder · 2025-10-31 from the prior October call. This stability is crucial for the high cost outlier dynamics that have pressured CIRH margins.
Outpatient: Rebuilding Margins
Outpatient rehabilitation delivered 4% revenue growth, but adjusted EBITDA fell to $22M from $24.3M, with margin at 6.8%. Management is addressing this through schedule optimization and market exits. As Tom Mullen noted, "we closed four clinics in Oregon" as part of this process. The company is also benefiting from a modest Medicare rate increase for 2026 after five years of cuts, which CFO Michael Malatesta referenced in the prior call: “In regards to health insurance expense, for the outpatient division, the impact was approximately $5 million for the quarter... both added together is around $11 million.” — Michael Malatesta, Chief Financial Officer · 2026-02-20 This quarter, the health insurance impact was less pronounced, but the mix shift remains a watch item.
Financial Position and Outlook
Total revenue increased 5% to $1.4B, but operating margin slipped to 6.9% . With net leverage at 3.75x and the added debt from the take-private, the balance sheet is a focus. The company maintained guidance for the full year, as shown above. The new capital structure will be a key variable for investors and lenders alike.